Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Lundbeck Delivers Some Data-Driven Upside

Danish specialty pharmaceutical company H Lundbeck A/S (OTCPK:HLUYY) (LUN.CO) is facing down some steep patent cliffs, as about two-thirds of the company's first revenue loses patent protection over the next two and a half years. Management hopes that significant new drugs launched with partners Takeda (OTCPK:TKPYY) and Otsuka (OTCPK:OTSKY) will more than fill the gap, and some recent updates on key drug Brintellix have been positive. Lundbeck is also looking at upside potential from desmoteplase, brexpiprazole, and Northera (which Lundbeck is acquiring in its announced deal for Chelsea Therapeutics (NASDAQ:CHTP)), though these are higher-risk options today. All told, while Lundbeck remains a risky proposition, there is still upside to over $30.

Brintellix...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details